309.98
+16.98
+(5.80%)
At close: January 21 at 2:24:42 PM CST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in CNY | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 3 | 32 | 35 |
| Avg. Estimate | 16.09B | 14.17B | 41.53B | 71.15B |
| Low Estimate | 15.73B | 12.25B | 39.51B | 48.43B |
| High Estimate | 16.54B | 16.22B | 46.94B | 102.95B |
| Year Ago Sales | 13.05B | 6.55B | 30.68B | 41.53B |
| Sales Growth (year/est) | 23.31% | 116.42% | 35.38% | 71.33% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| XPEVN.MX | -- | -- | -- | -- |
| S&P 500 | 9.34% | 11.29% | 14.06% | 13.55% |
Upgrades & Downgrades
| Downgrade | UBS: Neutral to Sell | 12/5/2024 |
| Upgrade | China Renaissance: Hold to Buy | 11/22/2024 |
| Maintains | Citigroup: Neutral to Neutral | 11/20/2024 |
| Maintains | Bernstein: Market Perform to Market Perform | 11/20/2024 |
| Upgrade | JP Morgan: Neutral to Overweight | 9/5/2024 |
| Maintains | Citigroup: Neutral to Neutral | 8/21/2024 |